Royal Bank of Canada’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9K | Buy |
11,146
+5,893
| +112% | +$4.97K | ﹤0.01% | 6230 |
|
|
2025
Q4 | $5K | Sell |
5,253
-9,652
| -65% | -$7.92K | ﹤0.01% | 6732 |
|
|
2025
Q3 | $11K | Sell |
14,905
-81,263
| -85% | -$368K | ﹤0.01% | 6462 |
|
|
2025
Q2 | $487K | Buy |
96,168
+71,463
| +289% | +$281K | ﹤0.01% | 4486 |
|
|
2025
Q1 | $75K | Sell |
24,705
-214,432
| -90% | -$782K | ﹤0.01% | 5386 |
|
|
2024
Q4 | $865K | Buy |
239,137
+120,139
| +101% | +$364K | ﹤0.01% | 3675 |
|
|
2024
Q3 | $209K | Buy |
118,998
+105,148
| +759% | +$191K | ﹤0.01% | 4787 |
|
|
2024
Q2 | $22K | Sell |
13,850
-1,673
| -11% | -$2.91K | ﹤0.01% | 6043 |
|
|
2024
Q1 | $30K | Sell |
15,523
-75,768
| -83% | -$132K | ﹤0.01% | 5749 |
|
|
2023
Q4 | $128K | Buy |
91,291
+10,318
| +13% | +$13.2K | ﹤0.01% | 5467 |
|
|
2023
Q3 | $128K | Sell |
80,973
-3,456
| -4% | -$6.4K | ﹤0.01% | 5191 |
|
|
2023
Q2 | $182K | Buy |
84,429
+7,356
| +10% | +$16.1K | ﹤0.01% | 4839 |
|
|
2023
Q1 | $161K | Buy |
77,073
+5,305
| +7% | +$11.6K | ﹤0.01% | 4803 |
|
|
2022
Q4 | $157K | Buy |
71,768
+23,041
| +47% | +$54.3K | ﹤0.01% | 5091 |
|
|
2022
Q3 | $147K | Buy |
48,727
+48,183
| +8,857% | +$161K | ﹤0.01% | 5022 |
|
|
2022
Q2 | $1K | Sell |
544
-790
| -59% | -$2.86K | ﹤0.01% | 7230 |
|
|
2022
Q1 | $7K | Buy |
1,334
+834
| +167% | +$4.73K | ﹤0.01% | 7138 |
|
|
2021
Q4 | $4K | Buy |
+500
| New | +$4.17K | ﹤0.01% | 7294 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 7920 |
|
|
2021
Q2 | $0 | Buy |
+1
| New | +$4 | ﹤0.01% | 7735 |
|
|
2020
Q1 | – | Sell |
-1
| Closed | – | – | 7095 |
|
|
2019
Q4 | $0 | Buy |
+1
| New | +$4 | ﹤0.01% | 7183 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | – | – | 7205 |
|
|
2019
Q2 | $0 | Sell |
1
-3
| -75% | -$20 | ﹤0.01% | 7255 |
|
|
2019
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 7159 |
|
|
2018
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 7174 |
|
|
2018
Q3 | $0 | Buy |
+4
| New | +$44 | ﹤0.01% | 6989 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | – | – | 6950 |
|
|
2017
Q3 | $0 | Buy |
+1
| New | +$46 | ﹤0.01% | 7030 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | – | – | 6805 |
|
|
2017
Q1 | $0 | Buy |
+1
| New | +$46 | ﹤0.01% | 6855 |
|
|
2015
Q4 | – | Sell |
-24
| Closed | -$3K | – | 6845 |
|
|
2015
Q3 | $3K | Sell |
24
-5
| -17% | -$1.14K | ﹤0.01% | 6315 |
|
|
2015
Q2 | $8K | Buy |
+29
| New | +$9.01K | ﹤0.01% | 6135 |
|
Other funds holding ATYR
VCM
GCP
Royal Bank of Canada's ATYR Position: Q1 2026 in Review
Royal Bank of Canada increased its aTyr Pharma (ATYR) stake by 112% in Q1 2026, buying an estimated $4.97K and bringing the position to 11,146 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #6230.
Royal Bank of Canada first reported a position in ATYR in Q2 2015 and has held it in 28 quarters since. The position peaked at $865K in Q4 2024. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.
- Royal Bank of Canada held 11,146 shares of aTyr Pharma worth $9K as of Q1 2026.
- Royal Bank of Canada bought 5,893 aTyr Pharma shares in Q1 2026, an estimated $4.97K.
- aTyr Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6230 holding.
- Royal Bank of Canada first reported a position in aTyr Pharma in Q2 2015 and has held it in 28 quarters since.
- Royal Bank of Canada's aTyr Pharma position peaked at $865K in Q4 2024.
- 111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.